Maze Therapeutics, Inc. (NASDAQ: MAZE) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Maze Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.87, Maze Therapeutics, Inc. trades at 89.4x sales and 4.6x book value. Over the last twelve months it generated about $20M of revenue and a net loss of $158M. It runs a gross margin of 95.3%, an operating margin of -820.8% and a net margin of -757.4%. It shows return on equity of -38.4%, return on invested capital of -33.6% and a free cash flow yield of -6.4%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 14.14. Over the past 52 weeks the share price ranged from $21.95 to $53.65, with a beta of 2.03.
Maze Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Maze Therapeutics, Inc. (MAZE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.29% / 30% · (Cash+Inv) / Mkt Cap (36m) 28.0% / 30% · Interest income / Revenue 452300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.29% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.9% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 452300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.29% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.9% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 452300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 6.29% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 80.4% / 33.33% · Receivables / Avg Assets (4Q) 1.23% / 33.33% · Interest income / Revenue 452300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 7.65% / 33.33% · (Cash+ST Inv) / Total Assets 76.2% / 33.33% · (Cash+Recv) / Total Assets 76.2% / 33.33% · Interest income / Revenue 452300000.0% / 5% | Fail |
No. As of September 2026, Maze Therapeutics, Inc. (MAZE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Maze Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 452300000.0% of each dividend: Maze Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.